JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 2, 2004; DOI: 10.1124/jpet.104.067629


0022-3565/04/3111-237-245$20.00
JPET 311:237-245, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.067629v1
311/1/237    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurata, K.
Right arrow Articles by Yamawaki, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurata, K.
Right arrow Articles by Yamawaki, S.

NEUROPHARMACOLOGY

{beta}-Estradiol, Dehydroepiandrosterone, and Dehydroepiandrosterone Sulfate Protect against N-Methyl-D-aspartate-Induced Neurotoxicity in Rat Hippocampal Neurons by Different Mechanisms

Kenichi Kurata, Minoru Takebayashi, Shigeru Morinobu, and Shigeto Yamawaki

Department of Psychiatry and Neurosciences, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Japan (K.K., S.M., S.Y.); and Laboratory of Psycho-oncology, Institute of Clinical Research, National Hospital Organization Kure Medical Center, Hiroshima, Japan (M.T.)

We examined neuroprotective effects of {beta}-estradiol, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEA-S) against N-methyl-D-aspartate (NMDA)-induced neurotoxicity in primary cultured rat hippocampal neurons. All three steroids demonstrated neuroprotective effects. Time-course studies revealed that steroid cotreatment for only 15 min at the same time as exposure to NMDA, but neither pretreatment nor addition of steroids for 24 h after NMDA-mediated neuroprotective effects. This indicates that short-term actions of these steroids are critical for this process. Acute treatment with {beta}-estradiol dose dependently inhibited NMDA-induced intracellular Ca2+ increases, which strongly correlated with its neuroprotective effect via L-type voltage-gated calcium channels. Acute treatment with DHEA, but not with DHEA-S, significantly inhibited nitric oxide (NO) production and Ca2+-sensitive NO synthase (NOS) activity caused by NMDA stimulation. An NOS inhibitor, NG-monomethyl-L-arginine acetate was also protective against NMDA-induced neurotoxicity. These data indicate that {beta}-estradiol may exert neuroprotective effects mainly by reducing Ca2+ increases but that DHEA may act by inhibiting NOS activity. Treatment with the {sigma}-1 receptor (Sig-1R) antagonists rimcazole or BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride) partially, but significantly, reversed the neuroprotective effect of DHEA-S against NMDA-induced neurotoxicity, whereas muscimol, a GABA-A-receptor agonist, did not. This suggests that the neuroprotective effect of DHEA-S may be mediated via Sig-1R, at least in part. Together, our data suggest that the neurosteroid family members {beta}-estradiol, DHEA, and DHEA-S exert neuroprotective effects through different nongenomic mechanisms.


Received February 25, 2004; accepted May 28, 2004.

Address correspondence to: Dr. Shigeto Yamawaki, Department of Psychiatry and Neurosciences, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail: yamawaki{at}hiroshima-u.ac.jp




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. C. Naylor, C. M. Hulette, D. C. Steffens, L. J. Shampine, J. F. Ervin, V. M. Payne, M. W. Massing, J. D. Kilts, J. L. Strauss, P. S. Calhoun, et al.
Cerebrospinal Fluid Dehydroepiandrosterone Levels Are Correlated with Brain Dehydroepiandrosterone Levels, Elevated in Alzheimer's Disease, and Related to Neuropathological Disease Stage
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3173 - 3178.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Sicard, M. Ehrhart-Bornstein, D. Corbeil, S. Sperber, A. W. Krug, C. G. Ziegler, V. Rettori, S. M. McCann, and S. R. Bornstein
Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate
PNAS, February 6, 2007; 104(6): 2007 - 2012.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.